Home High-Flow Nasal Cannula Oxygen Therapy for Stable Hypercapnic COPD: A Randomized Clinical Trial

Area of Science:

• Respiratory Medicine
• Pulmonary Diseases
• Critical Care

Background:

• Chronic hypercapnic respiratory failure in COPD patients presents long-term management challenges.
• The efficacy of high-flow nasal cannula (HFNC) therapy in this population requires further investigation.

Purpose of the Study:

• To evaluate the impact of long-term HFNC use on exacerbation rates in COPD patients with chronic hypercapnic respiratory failure.
• To assess improvements in physiological parameters and quality of life.

Main Methods:

• A randomized controlled trial involving 104 participants (aged ≥40) with COPD stages 2-4 and daytime hypercapnia.
• Participants received either HFNC/long-term oxygen therapy (LTOT) or LTOT alone.
• Primary endpoint: moderate or severe exacerbation rate; secondary endpoints included blood gas values, SpO2, pulmonary function, quality of life, and 6-minute-walk test.

Main Results:

• HFNC significantly reduced the rate of moderate/severe exacerbations (adjusted mean ratio 2.85) and prolonged time to first exacerbation.
• Significant improvements were observed in health-related quality of life scores, peripheral oxygen saturation, and pulmonary function parameters.
• No safety concerns were identified during the study period.

Conclusions:

• Long-term HFNC therapy is a safe and effective option for managing stable hypercapnic COPD patients with a history of exacerbations.
• HFNC therapy offers a promising alternative for reducing exacerbations and improving patient outcomes.